General Medicine and Primary Care - Prova Education

33-48 of 142

Center of the Target: Which Patients Are Most Likely to Develop Gout?
Center of the Target: Which Patients Are Most Likely to Develop Gout?
MinuteCE®
Center of the Target: Which Patients Are Most Likely to Develop Gout?
Richard Johnson, MD; Abdul Abdellatif, MD, FASN
- Richard Johnson, MD
- Abdul Abdellatif, MD, FASN
MinuteCE®
The Underestimated Consequences of Uncontrolled Gout: Renal and Cardiovascular Implications
Richard Johnson, MD; Abdul Abdellatif, MD, FASN
- Richard Johnson, MD
- Abdul Abdellatif, MD, FASN
- John K. Botson, MD, RPh
- Brittany Weber, MD, PhD
What’s New About Gout? Rheumatology Perspective
What’s New About Gout? Rheumatology Perspective
MinuteCE®
What’s New About Gout? Rheumatology Perspective
Richard Johnson, MD; John K. Botson, MD, RPh
- Richard Johnson, MD
- John K. Botson, MD, RPh
Gout Beyond the Joints: What’s the Hidden Danger?
Gout Beyond the Joints: What’s the Hidden Danger?
MinuteCE®
Gout Beyond the Joints: What’s the Hidden Danger?
Richard Johnson, MD
- Richard Johnson, MD
Patient-Centered Communications and Shared Decision-Making in the Management of Obesity
Patient-Centered Communications and Shared Decision-Making in the Management of Obesity
CME/CE
Patient-Centered Communications and Shared Decision-Making in the Management of Obesity
Charles P. Vega, MD
0.25 credits
- Charles P. Vega, MD
0.25 credits
Case Challenge in Obesity Medical Management
Case Challenge in Obesity Medical Management
CME/CE
Case Challenge in Obesity Medical Management
Charles P. Vega, MD; Donna Ryan, MD
0.25 credits
- Charles P. Vega, MD
- Donna Ryan, MD
0.25 credits
What You Need to Know About Weight-Loss Medications
What You Need to Know About Weight-Loss Medications
CME/CE
What You Need to Know About Weight-Loss Medications
Charles P. Vega, MD; Donna Ryan, MD
0.25 credits
- Charles P. Vega, MD
- Donna Ryan, MD
0.25 credits
The NASH Epidemic: Highlights from the AMCP 2023 Symposium
The NASH Epidemic: Highlights from the AMCP 2023 Symposium
CME/CE
The NASH Epidemic: Highlights from the AMCP 2023 Symposium
Mazen Noureddin, MD, MHSc
- Mazen Noureddin, MD, MHSc
Strategies for Referral to AUD Treatment
Strategies for Referral to AUD Treatment
MinuteCE®
Strategies for Referral to AUD Treatment
Annie Levesque, MD, MSc; Ethan A. Cowan, MD
- Annie Levesque, MD, MSc
- Ethan A. Cowan, MD
Selecting an AUD Treatment: Disulfiram
Selecting an AUD Treatment: Disulfiram
MinuteCE®
Selecting an AUD Treatment: Disulfiram
Edwin A. Salsitz, MD, DFASAM; Ethan A. Cowan, MD
- Edwin A. Salsitz, MD, DFASAM
- Ethan A. Cowan, MD
Selecting an AUD Treatment: Acamprosate
Selecting an AUD Treatment: Acamprosate
MinuteCE®
Selecting an AUD Treatment: Acamprosate
Edwin A. Salsitz, MD, DFASAM; Ethan A. Cowan, MD
- Edwin A. Salsitz, MD, DFASAM
- Ethan A. Cowan, MD
How, When, and Why to Conduct Brief AUD Interventions
How, When, and Why to Conduct Brief AUD Interventions
MinuteCE®
How, When, and Why to Conduct Brief AUD Interventions
Edwin A. Salsitz, MD, DFASAM
- Edwin A. Salsitz, MD, DFASAM
Standardized Screening Tools for AUD
Standardized Screening Tools for AUD
MinuteCE®
Standardized Screening Tools for AUD
Edwin A. Salsitz, MD, DFASAM; Annie Levesque, MD, MSc
- Edwin A. Salsitz, MD, DFASAM
- Annie Levesque, MD, MSc
Epidemiology of AUD and Patient Stratification
Epidemiology of AUD and Patient Stratification
MinuteCE®
Epidemiology of AUD and Patient Stratification
Edwin A. Salsitz, MD, DFASAM; Annie Levesque, MD, MSc
- Edwin A. Salsitz, MD, DFASAM
- Annie Levesque, MD, MSc
Selecting an AUD Treatment: Naltrexone
Selecting an AUD Treatment: Naltrexone
MinuteCE®
Selecting an AUD Treatment: Naltrexone
Ethan A. Cowan, MD; Edwin A. Salsitz, MD, DFASAM
- Ethan A. Cowan, MD
- Edwin A. Salsitz, MD, DFASAM
Selecting an AUD Treatment: Off-Label Agents
Selecting an AUD Treatment: Off-Label Agents
MinuteCE®
Selecting an AUD Treatment: Off-Label Agents
Ethan A. Cowan, MD; Edwin A. Salsitz, MD, DFASAM
- Ethan A. Cowan, MD
- Edwin A. Salsitz, MD, DFASAM

3/8